Heart Failure Patients Clinical Trial
Official title:
Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study
Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor with the ability to reduce myocardial hypertrophy, cardiac remodeling and cardiorenal fibrosis. The compound is also believed to have antiarrhythmic properties as it has been shown to significantly reduce ventricular arrhythmias in patients with implantable cardioverter defibrillators. Patients suffering from heart failure with reduced ejection fraction show impaired heart rate variability, knowing that in these patients such impairment is highly associated with an increased risk of sudden cardiac death. In its pivotal study, sacubitril/valsartan demonstrated a significant advantage over enalapril in terms of cardiovascular mortality and rehospitalization. Against this background, this study was designed to analyze the largely unknown electrophysiological effects of sacubitril/valsartan on the autonomic cardiac nervous system by determining heart rate variability.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03859466 -
Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting
|
N/A | |
| Completed |
NCT02571270 -
12-Week-Combined Physical Training In Heart Failure Patients
|
N/A | |
| Not yet recruiting |
NCT06426368 -
Soluble ST2 in Patients With Heart Failure"
|
||
| Completed |
NCT03701854 -
Physical Impairments in Heart Failure Patients With Pacemakers
|
||
| Recruiting |
NCT04434716 -
Monitoring and Self-management of Sleep Fatigue and Dyspnea
|
N/A |